Papillary Craniopharyngioma: Dabrafenib and Trametinib Treatment

We are studying how well the medications dabrafenib and trametinib reduce tumor size in patients with papillary craniopharyngioma. The trial also looks at how these treatments affect quality of life and other health aspects.

1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOralNeurologyOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Zelboraf
Zelboraf is a medicine used to treat melanoma (a type of skin cancer) that has spread and has a specific gene change.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Dabrafenib
Dabrafenib is a substance that targets a specific gene mutation to treat certain cancers, especially melanoma.
Trametinib
Trametinib is a substance that treats certain cancers by blocking cell signals that cause cancer cells to grow.
Vemurafenib
Vemurafenib is a substance that targets a specific BRAF mutation to slow growth of certain cancers, especially advanced melanoma.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Sahlgrenska University Hospital-Vaestra Goetalandsregionen
VO onkologi
Göteborg, Sweden
Region Vaesterbotten
Cancercentrum
Umeå, Sweden
Sponsor: Region Skane
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.